Abstract
The purpose of this study was to elucidate if the adiponectin level correlates with the survival of joint replacements. Current data indicates that adiponectin regulates lipid and glucose metabolism and acts anti-inflammatory and anti-apoptotic. We compared the value of adiponectin in serum taken from patients with early loosening in the first 10 years after implantation with serum from patients with late loosening and from patients without any kind of arthroplasty. Adiponectin was measured using a human Adiponectin ELISA test kit. Serum levels of adiponectin were significantly (p < 0.001) lower in patients with a short hip arthroplasty survivorship of up to 10 years (4.10 mg/microL) in comparison with those from patients undergoing exchange hip arthroplasty later than 10 years after primary surgery (10.86 mg/microL). We speculate that increased adiponectin serum levels may be associated with increased survival of hip replacements by reducing wear particle-induced inflammatory reactions and promoting clearance of apoptotic cell remnants. In conclusion, patients with low levels of adiponectin may have a significantly higher risk for early aseptic loosening when compared with patients with a high level.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call